Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types

杜皮鲁玛 医学 皮质类固醇 不利影响 大疱性类天疱疮 内科学 类天疱疮 免疫学 免疫失调 队列 回顾性队列研究 胃肠病学 抗体 疾病 特应性皮炎
作者
Tianmeng Yan,Yinghan Xie,Yuhua Liu,Ying Shan,Xiaoyan Wu,Jing Wang,Ya‐Gang Zuo,Zhenying Zhang
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:14 被引量:13
标识
DOI:10.3389/fimmu.2023.1194088
摘要

Background Bullous pemphigoid (BP) is an autoimmune skin-blistering disease. Systemic corticosteroids remain the first line treatment for moderate-to-severe BP with the potential for severe adverse events. Dupilumab has emerged as an alternative option for BP patients. Objective We evaluated the efficiency and safety of dupilumab on BP treatment and explored a mode of drug action in depth. Methods and results A multicenter retrospective cohort included 20 BP patients who received dupilumab with or without systemic corticosteroid in dupilumab group, and 20 matched BP patients who received corticosteroid alone in conventional group. Serum samples were collected from 20 patients (10 from dupilumab group and 10 from conventional group) at baseline and week 4. Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. However, dupilumab did not decrease BP180 antibody despite an obvious clinical improvement. Comparative plasma proteomic analysis performed before and after treatment in 3 BP patients from dupilumab group revealed that drug use was associated with 30 differentially expressed proteins, including 26 down-regulated and 4 up-regulated proteins. The former consisted of immune related proteins involved in T/B cell interactions (inducible T-cell co-stimulator ligand, ICOSL) and in the activation of eosinophils (PRG2), mast cells (S100A12), and complement (CR2). TARC and ICOSL levels correlated with BP severity in patients who received either dupilumab or conventional treatment. Conclusion Dupilumab has similar efficacy in treating BP as conventional drugs, by inhibiting the activities of many types of immune cells and complement, and regulating the interactions between T and B cells.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
洛克发布了新的文献求助10
刚刚
知足的憨人*-*完成签到,获得积分10
1秒前
1秒前
1秒前
大个的应助被桑桑采纳,获得10
1秒前
吃吃吃啥啦完成签到 ,获得积分10
2秒前
2秒前
清辉夜凝完成签到 ,获得积分10
2秒前
Felix发布了新的文献求助10
2秒前
kiwi发布了新的文献求助10
2秒前
3秒前
MUMU发布了新的文献求助10
3秒前
xxx完成签到 ,获得积分10
3秒前
4秒前
Hello的应助被布莱克采纳,获得10
4秒前
GIN的应助被李梨采纳,获得10
4秒前
5秒前
文艺宛筠发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
科研通AI6.3的应助被u596985采纳,获得10
5秒前
研友_VZG7GZ的应助被玩家666采纳,获得10
6秒前
木子木完成签到,获得积分10
6秒前
cheung发布了新的文献求助10
6秒前
ss完成签到,获得积分10
6秒前
LUsensei完成签到,获得积分20
7秒前
lkh发布了新的文献求助10
7秒前
周一发布了新的文献求助10
7秒前
充电宝的应助被何桉采纳,获得10
7秒前
昏睡的金毛完成签到,获得积分10
7秒前
orixero的应助被ZYT采纳,获得10
7秒前
Maestro_S的应助被ZYT采纳,获得30
7秒前
科研通AI6.2的应助被ZYT采纳,获得30
8秒前
wanci的应助被kiwi采纳,获得10
8秒前
想发A刊完成签到,获得积分10
8秒前
田様的应助被lucia采纳,获得10
8秒前
111发布了新的文献求助10
9秒前
炸薯条发布了新的文献求助10
9秒前
酷波er的应助被fyj采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193